Apimeds Pharmaceuticals US, Inc.

XASE

Last traded price · USD

$2.92

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:31 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $2.92
Volume: —
Day's high: —
Day's low: —

In brief

Apimeds Pharmaceuticals US, Inc. is a US-listed company listed on NYSE American, valued at about $4M.
Its shares closed at $2.92 on 4 Nov 2026.
From India you can buy APUS in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Apimeds Pharmaceuticals US, Inc. (APUS) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole APUS share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade APUS options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY over 3 months
1 month: −59.0% (SPY −1.6%). 3 months: −37.2% (SPY −0.4%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: APUS, SPY · as of 4 Nov 2026
Below its 50-day average
The 4 Nov 2026 close of $2.92 was 18.5% below its 50-day average ($3.58).
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Short interest at 4.8% of shares outstanding
73.0K shares were sold short at the 15 Oct 2026 settlement, 4.8% of the 1.5M shares outstanding; covering them would take 1.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−59.0%

6 months−85.0%

1 year—

5 years—

Newswire

About

Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.

Website

Notable moves

October 6, 2026
+55.34%
September 25, 2026
+47.36%
September 24, 2026
+114.85%

Newswire

About

Website

Notable moves

October 6, 2026
+55.34%
September 25, 2026
+47.36%
September 24, 2026
+114.85%

Apimeds Pharmaceuticals US, Inc.

XASE

Last traded price · USD

$2.92

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:31 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $2.92
Volume: —
Day's high: —
Day's low: —

In brief

Apimeds Pharmaceuticals US, Inc. is a US-listed company listed on NYSE American, valued at about $4M.
Its shares closed at $2.92 on 4 Nov 2026.
From India you can buy APUS in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Apimeds Pharmaceuticals US, Inc. (APUS) shares from India?

Do I need the price of a whole APUS share to invest?

How much can I invest in US stocks in a year?

Can I trade APUS options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY over 3 months
1 month: −59.0% (SPY −1.6%). 3 months: −37.2% (SPY −0.4%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: APUS, SPY · as of 4 Nov 2026
Below its 50-day average
The 4 Nov 2026 close of $2.92 was 18.5% below its 50-day average ($3.58).
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Short interest at 4.8% of shares outstanding
73.0K shares were sold short at the 15 Oct 2026 settlement, 4.8% of the 1.5M shares outstanding; covering them would take 1.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−59.0%

6 months−85.0%

1 year—

5 years—

Newswire

About

Website

Notable moves

October 6, 2026
+55.34%
September 25, 2026
+47.36%
September 24, 2026
+114.85%

Newswire

About

Website

Notable moves

October 6, 2026
+55.34%
September 25, 2026
+47.36%
September 24, 2026
+114.85%

Apimeds Pharmaceuticals US, Inc.

Apimeds Pharmaceuticals US, Inc. in brief

Behind SPY over 3 months

Below its 50-day average

Short interest at 4.8% of shares outstanding

Apimeds Pharmaceuticals US, Inc.

Apimeds Pharmaceuticals US, Inc. in brief

Behind SPY over 3 months

Below its 50-day average

Short interest at 4.8% of shares outstanding